Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the pathological and molecular responses associated with tr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sara A. Hurvitz, Jennifer L. Caswell-Jin, Katherine L. McNamara, Jason J. Zoeller, Gregory R. Bean, Robert Dichmann, Alejandra Perez, Ravindranath Patel, Lee Zehngebot, Heather Allen, Linda Bosserman, Brian DiCarlo, April Kennedy, Armando Giuliano, Carmen Calfa, David Molthrop, Aruna Mani, Hsiao-Wang Chen, Judy Dering, Brad Adams, Eran Kotler, Michael F. Press, Joan S. Brugge, Christina Curtis, Dennis J. Slamon
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3ed71c9a08f44623be4704bf23a0df55
record_format	dspace
spelling	oai:doaj.org-article:3ed71c9a08f44623be4704bf23a0df552021-12-02T17:32:26ZPathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)10.1038/s41467-020-19494-22041-1723https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df552020-11-01T00:00:00Zhttps://doi.org/10.1038/s41467-020-19494-2https://doaj.org/toc/2041-1723HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the pathological and molecular responses associated with trastuzumab and/or lapatinib in combination with chemotherapy in HER2+ breast cancer patients.Sara A. HurvitzJennifer L. Caswell-JinKatherine L. McNamaraJason J. ZoellerGregory R. BeanRobert DichmannAlejandra PerezRavindranath PatelLee ZehngebotHeather AllenLinda BossermanBrian DiCarloApril KennedyArmando GiulianoCarmen CalfaDavid MolthropAruna ManiHsiao-Wang ChenJudy DeringBrad AdamsEran KotlerMichael F. PressJoan S. BruggeChristina CurtisDennis J. SlamonNature PortfolioarticleScienceQENNature Communications, Vol 11, Iss 1, Pp 1-15 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Sara A. Hurvitz Jennifer L. Caswell-Jin Katherine L. McNamara Jason J. Zoeller Gregory R. Bean Robert Dichmann Alejandra Perez Ravindranath Patel Lee Zehngebot Heather Allen Linda Bosserman Brian DiCarlo April Kennedy Armando Giuliano Carmen Calfa David Molthrop Aruna Mani Hsiao-Wang Chen Judy Dering Brad Adams Eran Kotler Michael F. Press Joan S. Brugge Christina Curtis Dennis J. Slamon Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
description	HER2+ breast cancer patients can often develop resistance to trastuzumab and therefore potential combination therapies need to be explored. Here, the authors report the results of a multi-center randomized phase II clinical trial evaluating the pathological and molecular responses associated with trastuzumab and/or lapatinib in combination with chemotherapy in HER2+ breast cancer patients.
format	article
author	Sara A. Hurvitz Jennifer L. Caswell-Jin Katherine L. McNamara Jason J. Zoeller Gregory R. Bean Robert Dichmann Alejandra Perez Ravindranath Patel Lee Zehngebot Heather Allen Linda Bosserman Brian DiCarlo April Kennedy Armando Giuliano Carmen Calfa David Molthrop Aruna Mani Hsiao-Wang Chen Judy Dering Brad Adams Eran Kotler Michael F. Press Joan S. Brugge Christina Curtis Dennis J. Slamon
author_facet	Sara A. Hurvitz Jennifer L. Caswell-Jin Katherine L. McNamara Jason J. Zoeller Gregory R. Bean Robert Dichmann Alejandra Perez Ravindranath Patel Lee Zehngebot Heather Allen Linda Bosserman Brian DiCarlo April Kennedy Armando Giuliano Carmen Calfa David Molthrop Aruna Mani Hsiao-Wang Chen Judy Dering Brad Adams Eran Kotler Michael F. Press Joan S. Brugge Christina Curtis Dennis J. Slamon
author_sort	Sara A. Hurvitz
title	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
title_short	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
title_full	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
title_fullStr	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
title_full_unstemmed	Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
title_sort	pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase ii randomized trial in her2-positive breast cancer (trio-us b07)
publisher	Nature Portfolio
publishDate	2020
url	https://doaj.org/article/3ed71c9a08f44623be4704bf23a0df55
work_keys_str_mv	AT saraahurvitz pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT jenniferlcaswelljin pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT katherinelmcnamara pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT jasonjzoeller pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT gregoryrbean pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT robertdichmann pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT alejandraperez pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT ravindranathpatel pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT leezehngebot pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT heatherallen pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT lindabosserman pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT briandicarlo pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT aprilkennedy pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT armandogiuliano pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT carmencalfa pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT davidmolthrop pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT arunamani pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT hsiaowangchen pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT judydering pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT bradadams pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT erankotler pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT michaelfpress pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT joansbrugge pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT christinacurtis pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07 AT dennisjslamon pathologicandmolecularresponsestoneoadjuvanttrastuzumabandorlapatinibfromaphaseiirandomizedtrialinher2positivebreastcancertriousb07
_version_	1718380305412259840

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Ejemplares similares